As one of the first companies to file an abbreviated new drug application containing a paragraph IV certification for this product, Teva has obtained a 180-day period of marketing exclusivity.
As one of the first companies to file an abbreviated new drug application containing a paragraph IV certification for this product, Teva has obtained a 180-day period of marketing exclusivity.